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Acquired haemophilia A (AHA) is a very rare bleeding 
disorder, characterized by the spontaneous development 
of autoantibodies against coagulation factor VIII (FVIII) 
in non-haemophiliac patients. Patients with no history of 
bleeding sometimes suddenly present with severe ecchy-
mosis or muscle hematoma. The clinical manifestation is 
characterised by spontaneous haemorrhagic complications 
and a severe and often life-threatening bleeding. The in-
cidence is about 1.5 cases million/year, with a high mortal-
ity rate, and it can be fatal in 15–20% of the patients.1 
AHA has a biphasic age distribution, exhibiting a small 
peak from age 20 to 30 years and a large peak at age 60 
years and older. The disease is often present in patients 
older than 60 years of age, and the incidence is the same 
in both genders.6 No underlying disorder can be identifi ed 
in about 50% of the cases. The morbidity and mortality 
rates may be underestimated due to the high median age 
at the time of diagnosis.1–4
It is well known that approximately 50% of patients 
with AHA have or have had immune system disorders, 
Coll. Antropol. 40 (2016) 2: 139–143
Case report
Treatment of Severe Acquired Haemophilia A 
with Immunosuppressive Agent: A Case Report 
of One Patient
Željka Škunca1 and Ana Planinc Peraica2
1 General Hospital Zadar, Department of Hematology, Zadar, Croatia
2 Clinical Hospital »Merkur«, Clinic of Internal Medicine, Department of Hematology, Zagreb, Croatia
A B S T R A C T
Acquired haemophilia A (AHA) is a rare hemorrhagic disease caused by an autoantibody against coagulation factor 
VIII. Nonhaemophiliac patients develop autoantibodies (inhibitors) directed against the factor VIII circulating coagula-
tion protein. Disease is associated with an increased morbidity and mortality. Inhibitors against FVIII induce acute and 
life-threatening hemorrhagic diathesis because of abnormal blood clotting. FVIII inhibitors demonstrate bleeding disor-
ders and prolonged activated partial thromboplastin time and a normal prothrombin time. AHA should be considered in 
the differential diagnosis particularly in postpartum women and in the elderly patients with bleeding tendency. Treatment 
of acute hemorrhage is focused in the control of the acute bleeding episode and the long term suppression of the autoan-
tibody. In congenital hemophilia A with inhibitors, in which using repetitive infusions of high dose FVIII concentrates is 
effective for inhibitor eradication. This report present one patient treated with immunosuppressive regimens. The most 
effective fi rst-line treatment for the eradication of factor VIII autoantibodies is the combination of steroides and cyclophos-
phamide.
Key words: Acquired haemophilia A, Factor VIII inhibitors, treatment
Introduction
such as autoimmune diseases and lymphoproliferative 
disorders. This fact, as well as knowledge that autoanti-
bodies play a central role in AHA pathogenesis, indicates 
that modulation of the immune system or the autoimmune 
mechanism that generates autoantibodies is involved in 
AHA.22 The disease is associated with autoimmune dis-
eases, like systemic lupus erythematosus, rheumatoid 
arthritis, in pregnancy, drug associated (penicillin, sul-
phonamides, and chloramphenicol, methyldopa, after 
interferon-α therapy), with graft-versus-host disease, ery-
thema multiform, drug allergic reactions, asthma, chron-
ic obstructive pulmonary disease, solid tumours (prostate, 
lung, colon, pancreas, head, neck, breast, melanoma, kid-
ney)4–8 and hematologic malignancies (chronic lymphocytic 
leukaemia, non-Hodgkin lymphoma, multiple myeloma, 
Waldenstrom macroglobulinaemia, monoclonal gammopa-
thies).1,2,9,10,12–16,22
Clinical manifestations include severe and massive 
bleeding which is responsible for their relatively high mor-
tality rate. The most commonly affected organ is the skin, 
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especially at the site of injection or contusion. Intramus-
cular and gastrointestinal/intraabdominal bleeding are 
often involved. AHA is associated with postdelivery or 
excessive bleeding during surgery. Persistent bleeding 
after surgical procedures or catheter insertion may be the 
earliest symptom of AHA. Bleeding can range from mild 
to life-threatening.22,23 Bleeding sites with AHA differ 
from congenital haemophilia A and include deep muscle 
and retroperitoneal area, gastrointestinal, lung, urogeni-
tal and intracranial bleeding.1,3,4
The diagnosis of AHA is based on isolated prolongation 
of activated partial thromboplastin time (APTT) which 
does not normalize after the addition of normal plasma 
and identifi cation of a reduced FVIII level with evidence 
of FVIII inhibitor activity (titrated using the Bethesda 
assay).3,7,8,12,22
Nonhaemophiliac patients develop autoantibodies (in-
hibitors) directed against the circulating coagulation 
FVIII.7,8,10 These inhibitors induce acute and life-threat-
ening hemorrhagic diathesis due to abnormal blood clot-
ting.
FVIII is a cofactor for activated factor IX (FIXa) that 
forms the Xase (tenase) complex in the presence of Ca2+ 
and phospholipids and is essential for the intrinsic coagu-
lation system responsible for blood clotting. FVIII defi -
ciency causes dysfunction of the intrinsic system and re-
duces thrombin generation, resulting in a bleeding 
disorder.22 FVIII is mainly synthesized in the liver as a 
2,351 amino acid and 330-kDa single-chain precursor 
glycoprotein with a functional domain structure. After 
proteolytic processing, circulating mature FVIII protein 
is composed of a heterodimer of a heavy and a light chain.22
The FVIII inhibitors in AHA are polyclonal autoanti-
bodies, mostly IgG4 autoantibodies and less frequently 
IgG1 and IgG2 autoantibodies. In congenital haemophilia 
A inhibitors are polyclonal alloantibodies, bind to the A2, 
A3 or C2 domains. Anti-C2 antibodies interfere with the 
binding of FVIII to phospholipids and VWF, A2 and A3 
inhibitors block the binding of FVIII to factor X (FX) and 
FIXa, respectively, and obstruct the formation of the Xase 
complex.21,22
In approximately 50% of AHA patients, especially el-
derly patients, autoantibody development against factor 
VIII is idiopathic,14 indicating that the acquired inhibitors 
develop via an autoimmune mechanism. The underlying 
conditions are observed in the remaining 50% of patients.22
The treatment involves two aspects – the treatment of 
acute bleeding episodes and the eradication of antibodies.
Bleeding episodes in AHA are often severe and life 
threatening and presents with severe anemia. The treat-
ment is focused on the control of the acute bleeding episode 
with bypassing agents, like recombinant activated FVII 
(rFVIIa, NovoSeven) and activated prothrombin complex 
concentrate (aPCC, FEIBA). Activated prothrombin com-
plex concentrates (APCC) containing factors II (prothrom-
bin), VII, IX, and X or recombinant activated factor VII 
are commonly administered and have shown to be benefi -
cial in treating patients with AHA as well as congenital 
hemophilia A patients with inhibitors.13,14,22,23 In patients 
with low titters of inhibitors, 1-deamino-8-D-arginine va-
sopressin (DDAVP) or FVIII concentrate can help. Des-
mopressin stimulates the release of FVIII and VWF from 
endothelial cells and can provide a transient rise in 
FVIII:C levels to therapeutic levels may also be effective 
in AHA patients with low titers of inhibitors or an FVIII:C 
level >5%.22 While desmopressin has the advantages of 
being of low cost and safety, it does not entirely increase 
FVIII:C level to a therapeutic level and becomes less ef-
fi cacious with repetitive administration.22,23
The fi rst-line treatment includes the recombinant ac-
tivated FVII (rFVIIa) and aPCC until haemostasis is 
achieved.3,9,10 The European Acquired Haemophilia Reg-
istry (EACH2) shows that the treatment rFVIIa consists 
of a bolus injection range 84.7–102.9 μg/Kg every 2–6 
hours during 24–72 h.14,16,17 The dosage of this agent is 
based largely on experience in the treatment of congenital 
haemophilia A and inhibitors. No data on the duration of 
the treatment are available. Depending on the site, type 
and severity of the bleeding, the treatment lasting from 
24–72 h may be appropriate. RFVIIa is generally well 
tolerated, severe thrombotic complications may occur, 
such as myocardial infarction, arterial and venous throm-
bosis, pulmonary embolism and stroke. Further treatment 
after haemostasis is necessary to prevent re-bleeding in 
some cases.4,13,17
AHA patients have been treated with FVIII and cyclo-
phosphamide for approximately 30 years.5,11,15 The usual 
treatment involves administration of prednisolone at a 
dose of 1mg/kg combined with cyclophosphamide 50–100 
mg/day orally.15 Various immunosuppressive regimens, 
reduced the inhibitor titters to undetectable levels in 68% 
of the patients with low-titter inhibitors (less than 5BU/
mL).5,7,19,22 In high titter patients this may require several 
months. EACH2 results of the study suggest that steroids 
alone give up to 48% CR. Steroids combined with cyclo-
phosphamide resulted in more patients achieving a stable 
CR (70%).8,20,21,23 Azathioprine or cyclosporine have also 
been tested, with good responses.15 There is no evidence 
that one immunosuppressive therapy is clinically superior 
to all others in treating AHA or that a certain therapy 
should be chosen depending on inhibitor titer or the hem-
orrhagic status.22 These treatments are associated with 
serious side effects, especially in older patients.
High doses of immunoglobulin have been used with 
success, but the effect was incomplete and needed combi-
nation with other medications. Drugs needed to inhibit the 
production of FVIII inhibitors have proved to be more ef-
fective and safe.6,22
The anti CD20 monoclonal antibody, rituximab, has 
shown very good results given either as monotherapy or 
in combination with immunosuppressive regimens in pa-
tients who do not respond to standard immunosuppressive 
therapy.8,9,10,16 Rituximab, an anti-CD20 monoclonal anti-
body against CD20, depletes CD20+ cells by antibody-
dependent cellular toxicity, including apoptosis and com-
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plement mediated lysis. Rituximab has been shown to be 
effective in autoantibody-mediated disease, with little tox-
icity. The autoantibodies rapidly resolved in patients, but 
the alloantibody that developed after the recombinant 
FVIII treatment persisted for months. Rituximab has 
been used without or with other immunosuppressive 
agents.2,9,11,13,15,18,19,22
The patient’s age is an important risk factor. 50% of 
the patients with AHA were older than 65 years. Death is 
mainly caused by infection, a common complication of 
long-term immunosuppression or it is the result of extend-
ed bleeding. Elderly age and comorbidities of patients in-
crease the risk of tromboembolism. Rapid elimination of 
the inhibitor might prevent this complication.2,4,11,17 The 
meta analysis showed an overall mortality rate of up to 
16% for various treatment regimens, and patients in whom 
the inhibitor could not be eliminated had a mortality rate 
of 42%. The complications were associated with infections 
related to chemotherapy-induced neutropenia, particu-
larly in elderly patients.5,15 Most patients die within 1–2 
years of diagnosis, from comorbid conditions rather than 
bleeding, which is a rare cause of death in this condition.5
We are going to report one case with AHA with hae-
maturia and intramuscular hematoma, successfully treat-
ed with hFVIIa, cylophosphamide and corticosteroids.
The aim of this study is to describe our experience in 
treating a patient with AHA using European Acquired 
Haemophilia Registry (EACH2). The bleeding was con-
trolled during treatment with rFVIIa, and no subsequent 
bleeding episodes occurred. The inhibitor levels with im-
munosuppressive agent decreased to undetectable levels 
within a median of 6 weeks. During the long term follow-
up the patient hasn’t had episodes of reduced FVIII activ-
ity and bleeding.
Case Report
A 77 year-old man presented with a rapid early haema-
turia and muscle hematomas of the lower limbs. Cystos-
copy analysis did not give the cause of bleeding, and after 
cystoscopy haematuria persisted. The patient had a his-
tory of chronic obstructive pulmonary disease (COPD), 
and had a history of arterial hypertension and atrial fi -
brillation. Initial laboratory evaluations showed severe 
anaemia, with a haemoglobin level of 6.8 g/dL, a hemat-
ocrit of 19.6%, and a normal platelet count. His pro-
thrombin time (PT) and international normalized ratio 
(INR) were within normal reference ranges. His prolonged 
APTT was 2.16 (normal values <1.2), the FVIII level was 
15%, the FVIII inhibitor level was 98 Bethesda Units 
(BU)/mL, and FIX, FXI, XII were within normal ranges 
measured at the local laboratory. The routine renal and 
liver function tests were all within normal limits. The 
rheumatoid factor, C-reactive protein and complement fac-
tor C3 and C4 were within normal ranges. The antinuclear 
antibody and the anti-DNA antibody were negative. The 
Lupus anticoagulant test was negative. The serum levels 
of all tumour markers were within normal limits. The 
total body computed tomography (CT) scan of the thorax, 
neck and abdomen were normal, without pathologic forma-
tions.
The patient was initially treated with 2 units of packed 
red blood cells and 6 units of fresh frozen plasma without 
response. The patient was treated immediately with in-
travenous prednisone (1mg/Kg/day) and rFVIIa (Novo-
Seven, NovoNordisk) at 90 μg/Kg every 4 hours for the 
fi rst four days, when the bleeding stopped. Cyclophospha-
mide was administered orally (100mg/day). After one 
week the patient was stable and had no further bleeding 
episodes. His APTT, and FVIII inhibitor normalized at 
week 6. These parameters were evaluated monthly in the 
fi rst twelve months, then every 3 months. Cyclophospha-
mide was stopped 6 weeks after the eradication of the 
FVIII inhibitor. He had no subsequent bleeding events the 
following year and he was in complete remission. The pa-
tient is very well with good response. The patient’s char-
acteristics are summarized in Table 1. Fig 1. shows APTT 
and circulating FVIII inhibitors in acute phase bleeding 
and Fig. 2. shows APTT and FVIII cencentrate.
Discussion
The acquired haemophilia A is a potentially life threat-
ening bleeding disorder in patients without a previous 
personal or family history of bleeding caused by the im-























POPD= chronic obstructive pulmonary disease, APTT= activated 
partial tromboplastin time
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Our patient was 77 years old. The median age of pa-
tients at diagnosis of AHA was 78 and 74 years in the two 
largest cohort studies, with more than 80% of patients 
older than 65 years.17 The patient had a severe bleeding 
tendency with high inhibitor titters and critical bleeding 
at presentation. The underlying disease known to be as-
sociated with FVIII inhibitor was identifi ed in this pa-
tient.14,17
In the acute phase, it is necessary to stop the bleeding. 
The treatment of acute bleeding episodes consists of infu-
sion preparations with FVIII bypassing activity, and of 
the fi rst line haemostatic treatment to reduce the risk of 
thrombotic complications. The treatment of bleeding with 
FVIII concentrates is usually taken into consideration 
only for patients with low-titre inhibitor levels (<5BU/ml). 
The European Acquired Haemophilia Registry (EACH2) 
shows that the majority of patients have high-titre inhibi-
tors, such as rhFVIIa or APCC. prothrombin complex 
concentrate. Plasmapheresis for a rapid reduction of the 
inhibitor would probably be unsafe in hemodynamically 
unstable patients.15,16,17,18
Our patient had high FVIII inhibitor titters of 98 BU/
mL. The bleeding was controlled with rFVIIa (90μg/kg 
every 4 hours) during 4 days, and no subsequent bleeding 
episodes occurred. The inhibitor levels decreased to unde-
tectable levels within a median of 6 weeks. In our patient, 
cancer or autoimmune disease was excluded. Immunosup-
pression with cyclophosphamide and prednisone until 
remission was effective, and it was administered for long-
term reduction of the inhibitor of the titer.3,9,14 During the 
long term follow-up of the patient, he has not had a single 
episode of reduced FVIII activity and bleeding.
Our treatment approach has already been successfully 
implemented by other institutions. Our fi nding shows that 
treatment with rhFVIIa and immunosuppression agents, 
such as corticosteroids and cyclophosphamide, is very safe 
and effective in the treatment of acute haemorrhage and 
in the cure for patients with high titters FVIII inhibitors. 
Collins P. et al.(2013) in a large study indicates an equal 
number of patients receiving prednisone and prednisone 
and cyclophosphamide and have a median age that 
matched our patient with very good results. Other authors 
have similar results.8,17,19,21,23
Rituximab (Mabthera) was a very effective treatment 
as a single agent, and it was for patients with low inhibitor 
titters. Rituximab, a monoclonal antibody that targets the 
CD20 antigen, is a potential candidate to substitute the 
current immunosuppression. Rituximab alone may not be 
enough to treat patients with high inhibitor levels. Stasi 
et al. (2004.) found that rituximab and cyclophosphamide 
were required to achieve a full and durable response in 
those patients with inhibitor levels higher than 100 BU/
mL. A combination of rituximab and steroids was no more 
effective than rituximab alone.8
In conclusion, acquired haemophilia A is a rare disor-
der. Any acute or recent onset of bleeding symptoms in a 
patient with no previous history of bleeding, especially in 
elderly or post-partum patients, and an unexplained iso-
lated prolonged APTT suggest the diagnosis of AHA, and 
a prompt further investigation is indicated.3,4,18
The pathogenic antibody involved in AHA should be 
identifi ed and quantifi ed. The pathogenic antibody can be 
removed from the patient’s plasma with immunosuppres-




































































Fig. 1. This fi gure shows APTT (Normal value APTT- 26–36 s, 
FVIII 70–150 %). and FVIII inhibitors in Bethesda units
(BU/ml) in acute phase bleeding and return to normal levels 
after 6 weeks of follow-up.
Fig. 2. This fi gure shows APTT and FVIII concentrate, 
returning to normal levels after 6 weeks. (Normal value 
APTT- 26–36 s, FVIII 70–150 %).
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LIJEČENJE TEŠKE STEČENE HEMOFILIJE A S IMUNOSUPRESIVNIM LIJEKOVIMA: 
PRIKAZ SLUČAJA KOD JEDNOG BOLESNIKA
S A Ž E T A K
Stečena hemofi lija A je autoimuno oboljenje uzrokovano neobičnim poremečajem faktora zgrušavanja uzrokovano 
autoantitijelima na FVIII kod bolesnika koji nemaju hemofi liju. Dolazi do pojave antitijela (inhibitora) protiv FVIII. 
Antitijela protiv faktora VIII mogu izazavati akutna i po život opasna krvarenja zbog poremečenih faktora zgrušavanja 
krvi. Inhibitori FVIII mogu produžiti parcijalno tromboplastinsko vrijeme i normalno protrombinski vrijeme. Na AHA 
treba misliti u diferencijalnoj dijagnostici osobito nakon poroda kod žena i u starijih bolesnika kod kojih postoji sklonost 
ka krvarenju. Liječenje akutnog krvarenja je usmjereno na kontrolu akutne episode kravrenja I suzbijanje autoantitije-
la. Kod hemofi lije A s inhibitorima, pomaže davanje faktora VIII u visokim dozama. Mnoge imunosupresivne kombi-
nacije su opisane. Kortikosteroidi u kombinaciji s ciklofosfamidom daju rezultate s značajno postignutom kompletnom 
remisijom, koja se defi nira nepostojanjem inhibitora i prisutnim FVIII iznad 70 IU/dL. Takve terapijske opcije su pove-
zane s ozbiljnim nuspojavama, posebno kod starijih bolesnika. Ovaj rad opisuje jednog bolesnika liječenog imunosupre-
sivnom terapijom.
